For research use only. Not for human or animal consumption.
What it is
ARA-290 is a synthetic peptide of eleven amino acids. The sequence is pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser: an N-terminal pyroglutamate cap, one arginine, two glutamic acid residues, and a free carboxyl on the C-terminal serine. It corresponds to the aqueous-facing side of helix B of human erythropoietin.
The identity a genuine vial should match:
- Chemical name: ARA-290 (cibinetide; also pHBSP, pyroglutamate helix B surface peptide)
- Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- CAS number: 1208243-50-8
- Molecular formula: C51H84N16O21
- Molecular weight: 1257.30 average; 1256.60 monoisotopic
- Form: lyophilised (freeze-dried) powder
- Storage: −20 °C, desiccated, protected from light
PubChem CID 91810664 returns that formula and mass for that CAS number, and its structure record carries the 5-oxopyrrolidine-2-carbonyl N-terminus that defines the pyroglutamate form.
Three names sit on one molecule: cibinetide (the INN and USAN name), ARA-290 (the development code) and pHBSP (used across the renal and cardiac literature). All resolve to CAS 1208243-50-8. A catalogue listing cibinetide and ARA-290 as separate items is listing the same compound twice.
Two structural facts drive everything below. The N-terminus is capped as pyroglutamate, formed with loss of ammonia from an N-terminal glutamine. And two glutamic acid residues plus the free C-terminal carboxyl outnumber the single arginine, so the molecule is net-acidic — it behaves differently when dissolving the powder than the basic peptides most catalogues are built around.
What researchers are studying
Each entry names a group, a model system and an endpoint, in the past tense. None of it establishes anything about use in a person.
Where the sequence came from. Brines and colleagues narrowed the tissue-protective region of erythropoietin to helix B, then to an eleven-residue fragment of its aqueous face, and examined that fragment in cell assays and rodent models. They reported no erythropoietic activity for either, and attributed the signalling they measured to a heterocomplex of the erythropoietin receptor and CD131 — the beta-common receptor — rather than the receptor homodimer that drives red cell production [1].
Receptor pharmacology. Collino and colleagues reviewed the pharmacokinetic and pharmacodynamic record in Pharmacology & Therapeutics in 2015, naming the peptide explicitly as pHBSP (ARA-290) [2]. That review reports a plasma half-life of approximately two minutes — the single most useful design constraint in the paper.
A rodent nerve preparation. Dilley’s Methods in Molecular Biology chapter documents the rat neuritis model: how it is induced, and how mechanical allodynia and heat hyperalgesia are measured, with data on ARA290 in that preparation [5]. It describes the model rather than an outcome.
In vitro metabolic fate. Thomas and colleagues at the German Sport University Cologne incubated ARA-290 in EDTA-, heparin- and citrate-plasma and in serum, then characterised the products by liquid chromatography with high-resolution mass spectrometry. They reported extensive exopeptidase-driven truncation with one predominant species, PyrEQLERALN [3] — the first nine residues, which independently confirm the published sequence and the pyroglutamate cap.
Analytical detection chemistry. ARA-290 appears by name among the sub-2 kDa peptides on the World Anti-Doping Agency prohibited list covered by a 2016 screening method: direct urine injection with liquid chromatography and ion-mobility time-of-flight mass spectrometry, limits of detection between 50 and 500 pg/mL, and −20 °C as the storage temperature for those specimens [4].
One small human study. Heij and colleagues at Leiden University Medical Center enrolled 22 participants in a double-blind, placebo-controlled exploratory design, 12 active and 10 placebo, at the amounts described in the paper. They reported that no safety concerns were raised by clinical or laboratory assessment, and a change relative to placebo on the screening-list instrument used in that study [6].
Where the evidence stops
A PubMed query for ARA-290 or cibinetide returned 60 records on 2026-08-20, none carrying a phase 3 publication type. Beyond the 22 participants above [6], the human record adds a double-blind study in 36 healthy participants — Eur Neuropsychopharmacol. 2015;25(12):2289-99, PMID 26431906 — which reported that what its authors measured did not clearly support the profile they set out to test.
Much of the foundational literature carries author affiliations to the developer: the 2008 paper [1] declares several authors as employees of Warren Pharmaceuticals, the 2015 review [2] lists two at Araim Pharmaceuticals. And one paper in the rodent ischemia-reperfusion subset, Mol Med. 2012;18:719-27, was retracted in February 2026 (retraction note Mol Med. 2026;32(1):31, PMID 41749083).
Names also drift inside the literature. A search for HBSP returns at least two molecules: the linear eleven-mer, and the thioether-cyclized analogue CHBP introduced in Biochim Biophys Acta. 2014;1842(11):2306-17, PMID 25220479, which compares itself explicitly against the linear peptide. Material attributed to ARA-290 in secondary write-ups sometimes belongs to that other compound.
How to verify a vial of ARA-290 before you pay
- A named third-party laboratory. The certificate should name an outside lab, not the seller’s own bench. Clarion’s current ARA-290 lot is analysed by Freedom Diagnostics Testing; the catalogue also uses Janoshik Analytical, resolved per lot from that lot’s own certificate rather than assumed across the catalogue.
- A lot number that matches the vial. Clarion publishes a public lot ledger in which a lot number resolves to that lot’s own signed certificate.
- A printed method and figure, not the word “tested.” Purity by HPLC main peak — Clarion’s published release specification is >99% — and identity by mass spectrometry, with the numbers on the page.
- The 17-dalton question. An uncapped eleven-mer of the same sequence computes to roughly 1274.3 average mass, about 17 daltons heavier than 1257.30. Chromatographic purity cannot say which is in the vial: both are the same eleven residues and elute as one main peak. A mass figure can. From the verified formula the capped molecule is 1256.60 monoisotopic, so the singly protonated ion sits near m/z 1257.61, the doubly protonated ion near m/z 629.31. Note the trap in that first number: 1257.61 is close to the average molecular weight, 1257.30, and they are different measurements. Substituting one for the other makes an identity comparison look done when it was never made.
- Cyclized is not one thing. CHBP is a separate molecule, compared directly against the linear peptide in the 2014 paper that introduced it. Copy calling ARA-290 a cyclic peptide conflates the small pyroglutamate ring with that analogue, and the study data attached to such copy often belongs to CHBP.
- Purity is a ratio, not a mass assay. A main-peak figure states what fraction of the eluting material is the target species, not how many milligrams of peptide the vial holds. Counterion, residual water and any bulking agent from lyophilisation sit inside the gross fill mass. Net peptide content is a separate determination.
Run all six against Clarion’s public lot ledger, the certificate linked from the [ARA-290 product page](https://clarionpeptides.## Common questions
What is ARA-290, in one line? A synthetic eleven-amino-acid peptide, CAS 1208243-50-8, C51H84N16O21, average molecular weight 1257.30, supplied as a lyophilised powder for research use only.
Are cibinetide and ARA-290 two different materials? No. Cibinetide, ARA-290, pHBSP and pyroglutamate helix B surface peptide all resolve to CAS 1208243-50-8 and PubChem CID 91810664.
Is it a cyclic peptide? Not in the sense vendor copy usually means. It is a linear eleven-mer with a small pyroglutamate ring at the N-terminus. CHBP is a separate compound with its own literature.
Does “>99%” mean 99% of the labelled milligrams are peptide? No. That is a chromatographic ratio, not a mass assay.
Is a non-erythropoietic peptide outside sport-governing-body lists? No — the two facts are independent. The 2008 paper reports no erythropoietic activity in the assays it ran [1], while the 2016 and 2017 method papers name ARA-290 among prohibited peptides [3][4].
How should it be stored, and is it a medicine? At −20 °C, desiccated and protected from light. It is a research-use-only material, not a medicine, and not for human or animal consumption.
References
Titles that state an outcome or name a condition are described rather than reproduced; all other bibliographic detail is unchanged.
- Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925-30. doi:10.1073/pnas.0805594105. PMID: 18676614. PMCID: PMC2504825.
- Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015 Jul;151:32-40. doi:10.1016/j.pharmthera.2015.02.005. PMID: 25728128.
- Thomas A, Knoop A, Schänzer W, Thevis M. Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports. Drug Test Anal. 2017 Nov;9(11-12):1799-1803. doi:10.1002/dta.2306. PMID: 28941172.
- Thomas A, Görgens C, Guddat S, et al. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci. 2016 Jan;39(2):333-41. doi:10.1002/jssc.201501060. PMID: 26578461.
- Dilley A. Methods Mol Biol. 2013;982:213-25. doi:10.1007/978-1-62703-308-4_14. PMID: 23456872. Subject: the rat neuritis model and its measurements.
- Heij L, Niesters M, Swartjes M, et al. Mol Med. 2012 Nov 15;18(1):1430-6. doi:10.2119/molmed.2012.00332. PMID: 23168581. PMCID: PMC3563705. Subject: a double-blind, placebo-controlled exploratory study in 22 participants. Title not reproduced: it names a condition.
Also verified: PMID 41749083, PMID 26431906, PMID 25220479. Every record here was confirmed against NCBI PubMed on 2026-08-20; no other literature is cited, because no other paper was verified for it.
Related: How to verify a peptide certificate of analysis.
ARA-290 (cibinetide, pHBSP), CAS 1208243-50-8, C51H84N16O21, average MW 1257.30. Release specification >99% by HPLC main peak, identity by mass spectrometry; the analysing laboratory and the figures for a given lot print on that lot’s own certificate, reachable from the QR code on the vial. For research use only. Not for human or animal consumption. Not a drug.
